Kenneth A. Cawkell, LLB – CEO
Ken is a founding principal and CEO of Neurodyn. He was involved in the conception and development of the company’s business plan and has been intimately involved in all aspects of the company’s development. He has over 25 years experience in the industry during which he has worked with and sits on the board of numerous public and private biotechnology companies. He has been involved in all stages of development of biotech companies, ranging from initial research and development projects through to the development, commercialization and sale of pharmaceutical products.
Robert L. Cervelli, M.Sc. – Executive Director
Robert has been an active serial entrepreneur in the life sciences sector in North America for over 25 years. Robert has had a founding role in biotechnology companies developing diagnostics, cancer therapy, vaccine enhancement technologies, neurological drug discovery and consumer health products. He has held leading roles in several US and Canadian agricultural biotech companies, including the first forest biotechnology company in Canada, and has become particularly knowledgeable in the commercial develop of botanical extracts and natural active compounds.
Denis G. Kay, Ph.D. – CSO
Denis is a graduate of Dalhousie (B.Sc. and M.Sc.) and McGill (Ph.D.) Universities. He is a founder, and Chief Scientific Officer of Neurodyn. Denis has more than 20 years experience in the development and characterization of small animal models of human diseases ranging from, models of the neurodegenerative diseases ALS and the vacuolar myelopathy associated with HIV infection of the CNS, to a patented model of the multi organ system disease of AIDS (co-inventor). He played an integral role in the design and implementation of the Neurodyn’s research and development program and is inventor on two of the Company’s families of patents pending.
H.A. Robertson Ph.D., FRSC – Director of Clinical Development
Harry graduated from the Universities of Western Ontario (B.A., M.Sc.) and Cambridge (Ph.D.) and is now Professor Emeritus of Pharmacology at Dalhousie University. He is a fellow of the Royal Society of Canada. Harry was the First Neurofortis Visiting Professor at Lund University in Sweden and is also an Adjunct Professor at the University of Prince Edward Island. Harry is co-founder of the Brain Repair Center (BRC) at Dalhousie University, and it’s first Director of Research. He is best known for discovering the role of the immediate early gene c-fos in brain and for his work on Parkinson’s and Huntington’s disease.
Jackalina M. Van Kampen, Ph.D. – Director of Preclinical Research
Dr. Jackalina M. Van Kampen is currently Director of Preclinical Research at Neurodyn Inc. as well as Adjunct Professor in the Department of Biomedical Science. She came to Neurodyn from the Mayo Clinic College of Medicine where she held the position of Assistant Professor of Molecular Neuroscience. Parkinson’s disease has been the main thrust of her career, beginning with graduate training under the supervision of Dr. A. Jon Stoessl, Director of the Pacific Parkinson’s Research Centre, and continuing through postdoctoral training with Dr. Harold Robertson, Research Director and co-founder of the Brain Repair Centre. She has established a research program focused primarily on neuroprotection and neuronal recovery in models of neurodegenerative disease and currently holds a CIHR grant, studying the neruorestorative potential of adult neurogenesis in a rodent model of Alzheimer’s disease. Dr. Van Kampen has also been working with Neurodyn to develop novel neuroprotective therapies for various neurological conditions, including Parkinson’s disease, Alzheimer’s disease, and ALS.
Dr. Alfred Maelicke, Ph.D. – Managing Director | Europe
Dr. Alfred Maelicke is Neurodyn’s Managing Director | Europe. A graduate of Goettingen and Saarbrucken Universities, he is both Founder and CEO of Galantos Pharma GmbH and has decades of experience in neuropharmacology, drug development, preclinical pharmacology and safety. He is the inventor of Memogain® – Neurodyn’s patent-protected synthetic derivative of the natural cognitive enhancer galantamine. In his role, he is managing clinical development of Memogain® in Alzheimer’s disease and other CNS indications, manufacturing and regulatory processes for market introduction, mode of action studies of nicotinic modulators, and formulation development for enhanced brain penetration.